top of page

Dr. Simon Malpas, CEO of Kitea Health, recently shared a truly inspiring journey on the See Tomorrow First podcast. His passion for transforming lives through technology is evident as he described the company's groundbreaking, fully implantable device, which is now in clinical trials. Unlike other companies in the field, such as Neuralink, which still rely on external-to-body components tethered systems, Kitea's innovative approach is truly pioneering.

 

Dr. Malpas shared the heart-wrenching stories like Janes, born with a chronic condition that required a shunt to drain excess fluid from her brain. This is a common procedure, but the reality is that these shunts often fail, leaving patients and families living in constant fear of the unknown. With a 50% failure rate within two years, the stress and anxiety experienced by these families is immeasurable.

 

Jane's story became a catalyst for the Kitea team, inspiring them to create a technology that could potentially change countless lives. The Kitea system is currently in patient studies, and early results are demonstrating a significant reduction in stress for patients and their families. By providing real-time data on intracranial pressure, the system can detect impending shunt failures, allowing for proactive medical intervention. This ability to anticipate and address crises is a game-changer, offering hope and peace of mind to those living with these conditions.

 

Kitea’s journey mirrors that of Cochlear, a pioneer in implantable medical devices. Both companies began with a relatively similar patient population addressing a specific, unmet need. Cochlear focused on profound deafness, while Kitea is tackling the challenges of intracranial pressure. While Cochlear’s technology stimulates the auditory nerve, Kitea’s innovative system senses and monitors pressure.

 

Cochlear has demonstrated the immense potential of this sector, boasting a market capitalization of over $20+ billion AUD. Kitea's technology, with its broader application across various pressure-related conditions, could position the company for even greater market penetration.

 

What sets Kitea apart is their unwavering focus on patient needs. Rather than simply developing a product and searching for a market, they identified a critical gap in patient care and engineered a solution to fill it. This patient-centric approach is at the heart of everything Kitea does.

 

Kitea Health is more than just a healthcare company; they are pioneers building a future where implantable technology can offer hope and healing. Dr. Malpas' appearance on the See Tomorrow First podcast gives a glimpse into Kitea’s world has given us a window into their world, and it's a vision that is both exciting and deeply meaningful. View the full podcast here, or listen on Spotify.


Kitea Health was honored to attend the 2024 Hydrocephalus Association Conference. Our team, Dr. Simon Malpas (CEO) and Natalia Lopez (COO), along with PhD candidate Sang Ho Kim, participated in the conference to deepen Kitea's understanding of the challenges faced by the hydrocephalus community.

A primary focus of for the attendance was to gather critical insights from patients and clinicians to inform our pivotal clinical trial. By connecting directly with those impacted by hydrocephalus, we aimed to ensure our research aligns with their priorities and needs. The conference also provided a valuable platform to collaborate with industry partners, accelerating our collective efforts to develop innovative treatments for this complex condition.

We extend our sincere gratitude to the Hydrocephalus Association for organizing such an important event. This platform fosters connection, knowledge sharing, and progress within the hydrocephalus community, and we commend the Association’s dedication to improving the lives of those affected.





The developer of the world's smallest brain implant, Kitea Health, says it not only alerts parents when pressure is building in their child's brain, but will take the pressure off families living in constant fear of a serious medical event.

Clinical trials have started in 20 people with hydrocephalus in Auckland.

Kitea Health CEO Dr Simon Malpas tells Bryan Crump typically hydrocephalus is treated by inserting a shunt in the brain - which can block.

The new Kitea Health brain Sensor is inserted at the same time as a shunt, can be monitored at home and will detect changes in brain pressure before symptoms, caused by blockages, appear.

Dr Malpas is joined by a family taking part in the trial.

Listen to the interview here.






bottom of page